HMGCR and hyperlipidemia: It can be deduced that the beneficial properties of MEACL against hyperlipidemia may be mediated in part through multiple mechanisms, including inhibition of HMG-CoA reductase, increased secretion of cholesterol and bile acids in the feces, and reduction of the endogenous synthesis of TC and TG in the liver.